• Myeloma UK
  • Clinical Service Excellence Programme
Top menu
Google+TwitterFacebook
Myeloma Academy
Myeloma Academy

Sign in | Register

Call us for more info on 0131 557 3332

Menu
  • Home
  • CPD & Learning
    • Myeloma Nurse Learning Programme
    • My CPD Portfolio
    • Challenging Cases
    • Tutorials
    • Seminars
    • Short Courses for Haematologists
    • Close
  • Library
    • Guidelines
      • BSH/UKMF
      • European myeloma network
      • IMWG
      • NICE
      • Close
    • Health Technology Assessment
    • Journal club
    • Patient Support and Information
      • Myeloma
      • AL amyloidosis
      • Close
    • Medical animations
    • Close
  • Resources
    • Nursing Best Practice Guides
    • Nurse role development
    • Assessment tools
    • Case reports
    • Myeloma Diagnosis Pathway
    • Myeloma Drug Finder
    • Myeloma Spotlight
    • Myeloma Trial Finder
    • Primary and secondary care education
    • RCGP Myeloma screencast
    • Close
  • News & Events
    • News
    • Event calendar
    • Meeting highlights
    • Close
  • CSEP
  • About Us
    • Contact Us
    • Close
MENU CLOSE back  

Daily Archives: July 8, 2019

daratumumab (Darzalex)

Daratumumab combination treatment approved for use on the NHS in Scotland

Myeloma patients at first relapse in Scotland will now be able to access the new treatment of daratumumab (Darzalex®), bortezomib (Velcade®) and dexamethasone on the NHS after it was approved for use by the Scottish Medicines Consortium (SMC). This decision brings Scotland into line with the rest of the UK following the decision by NICE…

July 8, 2019
Details
Myeloma Academy
Bottom menu

Charity No: SC 026116
Myeloma UK
22 Logie Mill
Beaverbank Business Park
Edinburgh
EH7 4HG